Does Grifols (BME:GRF) Offer Opportunity After Sharp Share Price Declines And Debt Concerns

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

If you are wondering whether Grifols at €9.22 is a bargain or a value trap, you are in the right place to size up what the current share price might actually represent. The stock has recently been weak, with a 7 day return of an 8.4% decline, a 30 day return of a 15.6% decline, a year to date return of a 17.7% decline, and a 5 year return of a 57.0% decline, which may have changed how investors see both its potential and its risks. Recent headlines around Grifols have mainly focused on its debt load, governance questions, and the strength of its plasma based medicines business. Together, these shape how comfortable investors feel with the balance sheet and future funding needs. These stories help explain why the share price has been under pressure and why opinions on the stock are currently quite divided. On our checks, Grifols scores 5 out of 6 on valuation, and you can see the full breakdown in its valuation score. Next, we will look at what traditional methods like P/E, P/S and discounted cash flow can tell you about that result, then finish with a more complete way to think about valuation that brings all of this together.

Find out why Grifols's -0.9% return over the last year is lagging behind its peers.

Approach 1: Grifols Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash Grifols is expected to generate in the future and discounts those amounts back to what they are worth in € today. The idea is simple: you are asking what a stream of future cash flows is worth right now.

For Grifols, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about €657.2 million. Analysts have provided explicit Free Cash Flow estimates out to 2030, with Simply Wall St extrapolating further years based on those inputs. Within that set of projections, the Free Cash Flow figure for 2030 is €1,618 million, and the discounted values for the years 2026 to 2035 range from roughly €495.0 million to €975.7 million per year.

When all those discounted cash flows are added together, the model arrives at an estimated intrinsic value of €25.19 per share. Compared with the current share price of €9.22, this suggests the stock is trading at a 63.4% discount to this DCF-based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Grifols is undervalued by 63.4%. Track this in your watchlist or portfolio, or discover 225 more high quality undervalued stocks.

Story Continues

GRF Discounted Cash Flow as at Mar 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Grifols.

Approach 2: Grifols Price vs Earnings

For profitable companies, the P/E ratio is a useful way to relate what you are paying for each share to the earnings that business is currently generating. It gives you a quick sense of how many euros investors are willing to pay today for one euro of earnings.

What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to justify a lower one.

Grifols currently trades on a P/E of 15.61x. That sits below the Biotechs industry average of roughly 28.00x and also below the peer group average of 34.82x. Simply Wall St’s Fair Ratio for Grifols is 35.46x, which is its proprietary view of what the P/E could be given factors like earnings growth, industry, profit margin, market cap and risk profile.

The Fair Ratio is more tailored than a simple industry or peer comparison because it adjusts for Grifols specific characteristics rather than assuming all Biotech companies deserve the same multiple. With a Fair Ratio of 35.46x versus the current 15.61x, Grifols screens as trading below that Fair Ratio based assessment.

Result: UNDERVALUEDBME:GRF P/E Ratio as at Mar 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 98 top founder-led companies.

Upgrade Your Decision Making: Choose your Grifols Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, which are simple stories you create about Grifols. These stories connect your view of its plasma therapies, debt and competitive threats to specific assumptions for future revenue, earnings and margins. They then connect those assumptions to a Fair Value that you can compare with the current price to decide whether you are comfortable buying, holding or selling, all within the Narratives tool on Simply Wall St’s Community page that millions of investors use. Those Narratives refresh automatically when new earnings or news arrive. One investor might build a more optimistic Grifols Narrative that lines up with a Fair Value around €21.72 based on higher growth and margins, while another might build a cautious Narrative closer to €9.00 that reflects lower growth, tighter margins and a lower future P/E. Both can see their story expressed clearly in numbers.

For Grifols however, we will make it really easy for you with previews of two leading Grifols Narratives:

🐂 Grifols Bull Case

Fair value in this bullish Narrative is set at €15.08.

At the last close of €9.22, this implies the shares are trading about 38.9% below that Narrative fair value based on ((15.08 - 9.22) / 15.08).

Revenue growth in this Narrative is set at 5.63% per year.

Assumes steady global demand for plasma based therapies, with Grifols using network expansion and process improvements to support revenue growth and better margins. Builds in higher free cash flow and gradual balance sheet improvement, with deleveraging helping to support earnings quality over time. Accepts ongoing risks from pricing pressure, currency moves, competition and debt, but treats them as manageable within the current analyst case.

🐻 Grifols Bear Case

Fair value in this bearish Narrative is set at €9.00.

At the last close of €9.22, this implies the shares are trading about 2.4% above that Narrative fair value based on ((9.22 - 9.00) / 9.00).

Revenue growth in this Narrative is set at 5.32% per year.

Assumes slower growth for plasma derived products as gene therapies, synthetic biologics and tighter healthcare budgets gradually limit the addressable market. Builds in pressure on margins from regulation, donor costs and compliance, even though earnings still rise from today’s level in the underlying assumptions. Requires a much lower future P/E multiple compared with today, reflecting the view that the market may price in higher risk and more muted long term expectations.

Taken together, these Narratives frame the current debate around Grifols. If you lean closer to the bullish story, you may see the current price as leaving more upside to a higher fair value. If you lean closer to the bearish view, you may see the recent share price weakness as not yet fully reflecting the risks around long term demand, margins and leverage.

Whichever side you find more convincing, using Narratives like these can help you pin your view of Grifols to clear numbers, rather than relying only on headlines or short term price moves.

Curious how numbers become stories that shape markets? Explore Community Narratives

Do you think there's more to the story for Grifols? Head over to our Community to see what others are saying!BME:GRF 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GRF.MC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments